What dose of intravenous fluorescein dye is administered during hysterectomy to assess ureteral patency?

Fluorescein Dosing for Ureteral Patency Assessment During Hysterectomy

Administer 25 mg of 10% intravenous sodium fluorescein (0.25 mL of the 100 mg/mL concentration) after vaginal cuff closure to assess ureteral patency during laparoscopic hysterectomy. 1

Recommended Dosing Protocol

The most robust evidence for fluorescein use during hysterectomy comes from a prospective observational study of 30 laparoscopic hysterectomy patients, which established the following protocol:

• Dose: 25 mg of 10% intravenous sodium fluorescein 1
• Timing: Administer after vaginal cuff closure, immediately before cystoscopy 1
• Visualization time: Expect bilateral ureteral jet coloration within approximately 1 minute of injection 1
• Success rate: 93% of patients demonstrated bilateral ureteral jet coloration 1

Available Formulations

The FDA-approved formulations provide flexibility in dosing:

• 10% solution: 100 mg/mL in 5 mL vials 2
• 25% solution: 250 mg/mL in 2 mL vials 2

For the recommended 25 mg dose, you would administer 0.25 mL of the 10% solution or 0.1 mL of the 25% solution.

Alternative Dosing Range

A broader dosing range of 0.25-1.0 mL of 10% sodium fluorescein (25-100 mg) has been reported in clinical practice, with all doses providing adequate visualization of ureteral jets 3. However, the lower 25 mg dose is preferred as it minimizes side effects while maintaining excellent visualization.

Clinical Performance

In a randomized controlled trial comparing four methods of ureteral patency assessment (phenazopyridine, sodium fluorescein, mannitol, and normal saline), sodium fluorescein demonstrated:

• Good surgeon satisfaction (median visual analog scale score of 20 mm, where 0 = most satisfied) 4
• No difference in surgery or cystoscopy times compared to other methods 4
• No increased adverse events including urinary tract infections during 189-day follow-up 4

The hysterectomy-specific study reported 90% of surgeons were highly satisfied with sodium fluorescein use 1.

Expected Side Effects

Common and expected side effects include:

• Yellow discoloration of urine: Occurred in 50% of patients (15/30) 1
• Transient hypotension: Reported in 10% of patients (3/30) 1
• Transient yellowing of sclera and palms: Rare, self-limited 3

These side effects are benign and self-resolving, requiring no intervention.

Critical Clinical Advantage

The key benefit of fluorescein is immediate intraoperative detection of ureteral obstruction. In the prospective study, one patient had complete unilateral ureteral obstruction that was immediately diagnosed and resolved intraoperatively after removal of vaginal sutures—this would have been missed without the dye assessment 1. This represents a significant quality-of-life and morbidity prevention benefit, as unrecognized ureteral injury can lead to serious complications including urinoma, sepsis, and potential nephrectomy.

Practical Considerations

• Fluorescein provides superior visualization compared to the now-discontinued indigo carmine 3
• The brilliant yellow ureteral jets are easily visible within minutes of injection 3
• No preoperative preparation is required, unlike oral phenazopyridine 4
• The method does not require ureteral stenting or catheterization, unlike indocyanine green techniques 5